삼성서울병원

Ko En

Hematology-Oncology Kang, Won Ki M.D

Expertise
gastric cancer, colorectal cancer
Treament Schedule 02 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
AM
PM
Treament Schedule 03 月
DATE
SAT
01
SUN
02
MON
03
TUE
04
WEB
05
THU
06
FRI
07
SAT
08
SUN
09
MON
10
TUE
11
WEB
12
THU
13
FRI
14
SAT
15
SUN
16
MON
17
TUE
18
WEB
19
THU
20
FRI
21
SAT
22
SUN
23
MON
24
TUE
25
WEB
26
THU
27
FRI
28
SAT
29
SUN
30
MON
31
AM
PM

Medical Education

Seoul National University College of Medicine

Post-Graduate Training

Fellowship   1990~1991 Division of Hematology-Oncology, Dept of Internal Medicine,Seoul National University Hospital
Residency   1987~1990 Dept. of Internal Medicine, Seoul National University Hospital
Internship   1983~1984 Seoul National University Hospital

Professional Appointments

2011~Present Director Gastric Cancer Center, Samsung Cancer Center
2005~2011 Deputy Director Samsung Cancer Center
2005~2009 Chief Division of Hematology-Oncology, Dept of Medicine Samsung Medical Center
2002~Present Professor Dept. of Medicine, Sungkyunkwan University School of Medicine
1997~2002 Assistant Professor Dept. of Medicine, Sungkyunkwan University School of Medicine
1994~1997 Staff Division of Hematology-Oncology, Dept. of Medicine, Samsung Medical Center

Professional Memberships

Korean Cancer Association

Selected Publications

  • CANCERS 2024 10.3390/cancers16172969 The Impact of Pembrolizumab as a Salvage Therapy Based on HER2 Expression in Advanced Gastric Cancer Lim, SH; Kim, MJ; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • WORLD J GASTRO ONCOL 2024 10.4251/wjgo.v16.i8.3521 Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1 Kang, SW; Lim, SH; Kim, MJ; Lee, J; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCER DISCOV 2024 10.1158/2159-8290.CD-23-0857 Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer An, M; Mehta, A; Min, BH; Heo, YJ; Wright, SJ; Parikh, M; Bi, L; Lee, H; Kim, TJ; Lee, SY; Moon, J; Park, RJ; Strickland, MR; Park, WY; Kang, WK; Kim, KM; Kim, ST; Klempner, SJ; Lee, J
    View PubMed
  • EUR J CANCER 2024 10.1016/j.ejca.2024.114043 Prognostic and predictive impact of sex in locally advanced microsatellite instability high gastric or gastroesophageal junction cancer: An individual patient data pooled analysis of randomized clinical trials Raimondi, A; Kim, YW; Kang, WK; Langley, RE; Choi, YY; Kim, KM; Nankivell, MG; Randon, G; Kook, MC; An, JY; Grabsch, HI; Prisciandaro, M; Nichetti, F; Noh, SH; Sohn, TS; Kim, S; Wotherspoon, A; Morano, F; Cunningham, D; Lee, JY; Cheong, JH; Smyth, EC; Pietrantonio, F
    View PubMed
  • J GASTROINTEST ONCOL 2023 10.21037/jgo-23-598 The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer Jeon, Y; Lim, SH; Lee, J; Kang, WK; Jang, JY; Jeong, SY; Choi, D; Kim, ST
    View PubMed
  • J GASTROINTEST ONCOL 2023 10.21037/jgo-23-418 Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression Choi, DH; Lee, J; Lim, HY; Kang, WK; Jang, JY; Jeon, Y; Jeong, SY; Jung, YJ; Kim, ST
    View PubMed
  • BIOMEDICINES 2023 10.3390/biomedicines11113097 The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy Shin, MK; Choi, MG; Kim, ST; Kang, WK; Sohn, TS; An, JY; Lee, JH; Lee, JY
    View PubMed
  • SCI ADV 2023 10.1126/sciadv.adk1098 Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer Hyung, S; Ko, J; Heo, YJ; Blum, SM; Kim, ST; Park, SH; Park, JO; Kang, WK; Lim, HY; Klempner, SJ; Lee, J
    View PubMed
  • ONCOL RES 2023 10.32604/or.2023.030374 Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer Lim, SH; Cho, HJ; Kim, KM; Lim, HY; Kang, WK; Lee, J; Park, YS; Kim, HC; Kim, ST
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.6472 Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer Shin, M; Ahn, S; Jung, J; Hyung, S; Kim, KM; Kim, ST; Kang, WK; Lee, J
    View PubMed
  • J GASTRIC CANCER 2023 10.5230/jgc.2023.23.e29 The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer Jang, JY; Jeon, Y; Jeong, SY; Lim, SH; Kang, WK; Lee, J; Kim, ST
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1527 A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer Jo, H; Kim, ST; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Il Yu, J; Park, HC; Choi, DH; Park, Y; Cho, YB; Huh, JW; Yun, SH; Kim, HC; Lee, WY; Kang, WK
    View PubMed
  • PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • BIOMEDICINES 2022 10.3390/biomedicines10071565 Clinical Significance of Preoperative Hematological Parameters in Patients with D2-Resected, Node-Positive Stomach Cancer Park, JS; Yu, JI; Lim, DH; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
    View PubMed
  • J IMMUNOTHER CANCER 2022 10.1136/jitc-2022-005041 Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer Kwon, M; Kim, G; Kim, R; Kim, KT; Kim, ST; Smith, S; Mortimer, PGS; Hong, JY; Loembe, AB; Irurzun-Arana, I; Koulai, L; Kim, KM; Kang, WK; Dean, E; Park, WY; Lee, J
    View PubMed
  • CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • CANCER DISCOV 2022 10.1158/2159-8290.CD-21-0888 Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer Kim, R; An, M; Lee, H; Mehta, A; Heo, YJ; Kim, KM; Lee, SY; Moon, J; Kim, ST; Min, BH; Kim, TJ; Rha, SY; Kang, WK; Park, WY; Klempner, SJ; Lee, J
    View PubMed
  • J ONCOL 2022 10.1155/2022/9714570 Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • J CANCER 2022 10.7150/jca.67050 Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: A single-arm phase-II trial Kim, R; Ji, JH; Kim, JH; Hong, JY; Lim, HY; Kang, WK; Lee, J; Kim, ST
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.792340 The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers Kim, HR; Ahn, S; Jo, H; Kim, H; Hong, J; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
    View PubMed
  • GASTRIC CANCER 2021 10.1007/s10120-021-01230-4 Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study Kang, YK; Morita, S; Satoh, T; Ryu, MH; Chao, Y; Kato, K; Chung, HC; Chen, JS; Muro, K; Kang, WK; Yeh, KH; Yoshikawa, T; Oh, SC; Bai, LY; Tamura, T; Lee, KW; Hamamoto, Y; Kim, JG; Chin, K; Oh, DY; Minashi, K; Cho, JY; Tsuda, M; Sameshima, H; Chen, LT; Boku, N
    View PubMed
  • J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • CANCER DISCOV 2021 10.1158/2159-8290.CD-21-0219 Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability-High Gastric Cancer Kwon, M; An, M; Klempner, SJ; Lee, H; Kim, KM; Sa, JK; Cho, HJ; Hong, JY; Lee, TY; Min, YW; Kim, TJ; Min, BH; Park, WY; Kang, WK; Kim, KT; Kim, ST; Lee, J
    View PubMed
  • FRONT IMMUNOL 2021 10.3389/fimmu.2021.701668 Prognostic Impact of Sarcopenia and Radiotherapy in Patients With Advanced Gastric Cancer Treated With Anti-PD-1 Antibody Kim, N; Yu, JI; Lim, DH; Lee, J; Kim, ST; Hong, JY; Kang, WK; Jeong, WK; Kim, KM
    View PubMed
  • J CANCER RES THER 2021 10.4103/jcrt.JCRT_108_19 Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer Cho, JH; Sim, MH; Kim, SY; Kim, K; Lee, T; Lee, J; Kang, WK; Kim, ST
    View PubMed
  • INVEST NEW DRUG 2021 10.1007/s10637-021-01078-6 A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors Keam, B; Ock, CY; Kim, TM; Oh, D; Kang, WK; Park, YH; Lee, J; Lee, JH; Ahn, YH; Kim, HJ; Chang, SK; Park, J; Choi, JY; Song, YJ; Park, YS
    View PubMed
  • J CANCER 2021 10.7150/jca.62853 When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer Kim, H; Kim, H; Lee, M; Kwon, M; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • EUR RADIOL 2021 10.1007/s00330-021-08094-3 Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D
    View PubMed
  • GASTRIC CANCER 2021 10.1007/s10120-021-01173-w Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab Boku1, N; Satoh, T; Ryu, MH; Chao, Y; Kato, K; Chung, HC; Chen, JS; Muro, K; Kang, WK; Yeh, KH; Yoshikawa, T; Oh, SC; Bai, LY; Tamura, T; Lee, KW; Hamamoto, Y; Kim, JG; Chin, K; Oh, DY; Minashi, K; Cho, JY; Tsuda, M; Nishiyama, T; Chen, LT; Kang, YK
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • J CANCER 2021 10.7150/jca.49176 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCERS 2021 10.3390/cancers13010059 Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses Park1, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
    View PubMed
  • GENOME MED 2021 10.1186/s13073-021-00826-w Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial Kim1, ST; Sa, JK; Oh, SY; Kim, K; Hong, JY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043 Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial Yu1, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • GASTRIC CANCER 2020 10.1007/s10120-020-01124-x Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors Kim1, YY; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Sohn, I; Choi, D
    View PubMed
  • EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855 Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920926796 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
    View PubMed
  • Transl Cancer Res 2020 10.21037/tcr-19-1876 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152941 CDH1 mutations in gastric cancers are not associated with family history Choi1, S; Jang, J; Heo, YJ; Kang, SY; Kim, ST; Lee, J; Kang, WK; Kim, JW; Kim, KM
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.261 Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer Yoo1, GS; Park, HC; Yu, JI; Choi, DH; Cho, WK; Park, YS; Park, JO; Lim, HY; Kang, WK; Lee, WY; Kim, HC; Yun, SH; Cho, YB; Park, YA; Song, KD; Kim, SH; Ha, SY
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00713-1 Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients Kim1, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00706-0 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCERS 2020 10.3390/cancers12040943 Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer Yu1, JI; Park, HC; Lee, J; Choi, C; Kang, WK; Park, SH; Kim, ST; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Kim, S; Lim, DH
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
    View PubMed
  • ESMO OPEN 2020 10.1136/esmoopen-2020-000670 Clinical scoring system for the prediction of survival of patients with advanced gastric cancer Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
    View PubMed
  • Front Oncol 2020 10.3389/fonc.2020.00314 Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer Kim1, J; Kim, B; Kang, SY; Heo, YJ; Park, SH; Kim, ST; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • Genome Med 2020 10.1186/s13073-020-0717-8 Comprehensive pharmacogenomic characterization of gastric cancer Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-019-00691-z Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • VIRCHOWS ARCH 2020 10.1007/s00428-019-02653-2 PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation Kim1, HN; Jang, J; Heo, YJ; Kim, B; Jung, HR; Jang, Y; Kang, SY; Kim, ST; Lee, JY; Kang, WK; Kim, KM
    View PubMed
  • J ONCOL 2020 10.1155/2020/4659062 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
    View PubMed
  • BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9 Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY
    View PubMed
  • GASTRIC CANCER 2020 10.1007/s10120-019-00970-8 Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer Satoh1, T; Kang, YK; Chao, Y; Ryu, MH; Kato, K; Chung, HC; Chen, JS; Muro, K; Kang, WK; Yeh, KH; Yoshikawa, T; Oh, SC; Bai, LY; Tamura, T; Lee, KW; Hamamoto, Y; Kim, JG; Chin, K; Oh, DY; Minashi, K; Cho, JY; Tsuda, M; Tanimoto, M; Chen, LT; Boku, N
    View PubMed
  • GASTRIC CANCER 2019 10.1007/s10120-019-01034-7 A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Chen1, LT; Satoh, T; Ryu, MH; Chao, Y; Kato, K; Chung, HC; Chen, JS; Muro, K; Kang, WK; Yeh, KH; Yoshikawa, T; Oh, SC; Bai, LY; Tamura, T; Lee, KW; Hamamoto, Y; Kim, JG; Chin, K; Oh, DY; Minashi, K; Cho, JY; Tsuda, M; Sameshima, H; Kang, YK; Boku, N
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32228 Bridging genomics and phenomics of gastric carcinoma Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.01327 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017 Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study Kwon1, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM
    View PubMed
  • J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-51981-5 Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C
    View PubMed
  • ANTICANCER RES 2019 10.21873/anticanres.13785 Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • Transl Cancer Res 2019 10.21037/tcr.2019.09.27 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2019 10.1016/j.prp.2019.152434 CCNE1 amplification is associated with liver metastasis in gastric carcinoma Kim1, B; Shin, HC; Heo, YJ; Ha, SY; Jang, KT; Kim, ST; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • Am J Transl Res 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.401 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.379 A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK
    View PubMed
  • J MOL DIAGN 2019 10.1016/j.jmoldx.2019.02.007 Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing A Direct Comparison Study with Immunohistochemistry Choi1, S; Chu, J; Kim, B; Ha, SY; Kim, ST; Lee, J; Kang, WK; Han, H; Sohn, I; Kim, KM
    View PubMed
  • J Cancer 2019 10.7150/jca.30257 High delta-like ligand 4 expression correlates with a poor clinical outcome in gastric cancer Kim1, Y; Byeon, SJ; Hur, J; Lee, K; Kim, D; Ahn, JH; Lee, SH; You, WK; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ONCOLOGY-BASEL 2019 10.1159/000499628 Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial Miceli1, R; An, J; Di Bartolomeo, M; Morano, F; Kim, ST; Park, SH; Choi, MG; Lee, JH; Raimondi, A; Fuca, G; Sohn, TS; Bae, JM; Kim, S; Lim, DH; Kang, WK; Kim, KM; Pietrantonio, F; Lee, J
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • CANCER CHEMOTH PHARM 2019 10.1007/s00280-018-3753-y Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer Oh1, SY; Lee, S; Huh, SJ; Lee, J; Kim, ST; Park, SH; Lim, HY; Kang, WK; Kang, BW; Kim, JG; Lee, HJ; Kim, JH; Kang, JH; Kim, H
    View PubMed
  • PATHOL RES PRACT 2019 10.1016/j.prp.2018.11.010 MET is overexpressed in microsatellite instability-high gastric carcinoma Sim1, J; Heo, YJ; Bae, H; Shin, HC; Kim, B; Cho, J; Kim, ST; Lee, J; Kang, WK; Kim, KM
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdy550 Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer Sundar1, R; Huang, KK; Qamra, A; Kim, KM; Kim, ST; Kang, WK; Tan, ALK; Lee, J; Tan, P
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdy540 Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) Boku1, N; Ryu, MH; Kato, K; Chung, HC; Minashi, K; Lee, KW; Cho, H; Kang, WK; Komatsu, Y; Tsuda, M; Yamaguchi, K; Hara, H; Fumita, S; Azuma, M; Chen, LT; Kang, YK
    View PubMed
  • Oncoimmunology 2019 10.1080/2162402X.2018.1544442 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S187621 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • PATHOL RES PRACT 2019 10.1016/j.prp.2018.10.024 The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma Cho1, J; Kim, KM; Kim, HC; Lee, WY; Kang, WK; Park, YS; Ha, SY
    View PubMed
  • J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH
    View PubMed
  • RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-018-4995-0 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • GASTRIC CANCER 2018 10.1007/s10120-018-0794-1 Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 Kim1, HS; Ryu, MH; Zang, DY; Park, SR; Han, B; Kang, WK; Rha, SY; Jung, M; Kim, JS; Kang, BW; Lee, KH; Rho, SY; Kim, JH; Kim, KC; Cho, JW; Choi, DR; Lim, H; Kang, HS; Soh, JS; Kim, MJ; Seo, J; Kang, YK
    View PubMed
  • J Cancer 2018 10.7150/jca.26068 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST
    View PubMed
  • NAT MED 2018 10.1038/s41591-018-0101-z Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK
    View PubMed
  • J Cancer 2018 10.7150/jca.24948 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
    View PubMed
  • NAT COMMUN 2018 10.1038/s41467-018-04179-8 Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype Oh1, SC; Sohn, BH; Cheong, JH; Kim, SB; Lee, JE; Park, KC; Lee, SH; Park, JL; Park, YY; Lee, HS; Jang, HJ; Park, ES; Kim, SC; Heo, J; Chu, IS; Jang, YJ; Mok, YJ; Jung, W; Kim, BH; Kim, A; Cho, JY; Lim, JY; Hayashi, Y; Song, SM; Elimova, E; Estralla, JS; Lee, JH; Bhutani, MS; Lu, YL; Liu, WB; Lee, J; Kang, WK; Kim, S; Noh, SH; Mills, GB; Kim, SY; Ajani, JA; Lee, JS
    View PubMed
  • J Cancer 2018 10.7150/jca.25132 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • MOL CANCER THER 2018 10.1158/1535-7163.MCT-17-0535 MCT4 Expression Is a Potential Therapeutic Target in Colorectal Cancer with Peritoneal Carcinomatosis Kim1, HK; Lee, I; Bang, H; Kim, HC; Lee, WY; Yun, SH; Lee, J; Lee, SJ; Park, YS; Kim, KM; Kang, WK
    View PubMed
  • YONSEI MED J 2018 10.3349/ymj.2018.59.1.28 Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma Kim1, SM; Min, BH; Lee, J; An, JY; Lee, JH; Sohn, TS; Bae, JM; Kim, JJ; Kang, WK; Kim, S; Choi, MG
    View PubMed
  • INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • LANCET 2017 10.1016/S0140-6736(17)31827-5 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Kang1, YK; Boku, N; Satoh, T; Ryu, MH; Chao, Y; Kato, K; Chung, HC; Chen, JS; Muro, K; Kang, WK; Yeh, KH; Yoshikawa, T; Oh, SC; Bai, LY; Tamura, T; Lee, KW; Hamamoto, Y; Kim, JG; Chin, K; Oh, DY; Minashi, K; Cho, JY; Tsuda, M; Chen, LT
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22394 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22511 Elevated CEA is associated with worse survival in recurrent rectal cancer Cho1, WK; Choi, DH; Park, HC; Park, W; Yu, JI; Park, YS; Park, JO; Lim, HY; Kang, WK; Kim, HC; Cho, YB; Yun, SH; Lee, WY
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18182 Correlation between MEK signature and Ras gene alteration in advanced gastric cancer Ahn1, S; Brant, R; Sharpe, A; Dry, JR; Hodgson, DR; Kilgour, E; Kim, K; Kim, ST; Park, SH; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.3750 MerTK is a novel therapeutic target in gastric cancer Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J
    View PubMed
  • Oncoimmunology 2017 10.1080/2162402X.2017.1356150 Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity Park1, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18168 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.19985 Development of mesenchymal subtype gene signature for clinical application in gastric cancer Lee1, J; Cristescu, R; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.20492 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • J Cancer 2017 10.7150/jca.19458 The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST
    View PubMed
  • TRANSL ONCOL 2017 10.1016/j.tranon.2017.03.001 Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model Jang1, J; Kim, HK; Bang, H; Kim, ST; Kim, SY; Park, SH; Lim, HY; Kang, WK; Lee, J; Kim, KM
    View PubMed
  • J Cancer 2017 10.7150/jca.18286 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • CLIN CANCER RES 2017 10.1158/1078-0432.CCR-16-2211 Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project Sohn1, BH; Hwang, JE; Jang, HJ; Lee, HS; Oh, SC; Shim, JJ; Lee, KW; Kim, EH; Yim, SY; Lee, SH; Cheong, JH; Jeong, W; Cho, JY; Kim, J; Chae, J; Lee, J; Kang, WK; Kim, S; Noh, SH; Ajani, JA; Lee, JS
    View PubMed
  • J Cancer 2017 10.7150/jca.19582 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion Kim SY11, Ahn T2, Bang H3, Ham JS1, Kim J1, Kim ST1, Jang J1, Shim M1, Kang SY3, Park SH1, Min BH4, Lee H4, Kang WK1, Kim KM3, Park W2,5, Lee J1.
    View PubMed
  • Oncotarget. 2017 Feb 21;8(8):13320-13328. doi: 10.18632/oncotarget.14519. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability Cho J11, Lee J2, Bang H3, Kim ST2, Park SH2, An JY4, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kang WK2, Kim S4, Kim KM3.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
    View PubMed
  • Gastric Cancer. 2016 Oct;19(4):1095-103. doi: 10.1007/s10120-015-0567-z. Epub 2015 Nov 18. Phase II trial of dacomitinib in patients with HER2-positive gastric cancer Oh DY11,2, Lee KW3, Cho JY4, Kang WK5, Im SA1,2, Kim JW3, Bang YJ6,7.
    View PubMed
  • Mod Pathol. 2016 Sep;29(9):1095-103. doi: 10.1038/modpathol.2016.96. Epub 2016 May 27. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival Ahn S11,2, Lee J3, Hong M4, Kim ST3, Park SH3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Jung SH6, Kang WK3, Kim KM1,2.
    View PubMed
  • Mol Diagn Ther. 2016 Aug;20(4):375-83. doi: 10.1007/s40291-016-0205-4. A nCounter CNV Assay to Detect HER2 Amplification: A Correlation Study with Immunohistochemistry and In Situ Hybridization in Advanced Gastric Cancer Ahn S11,2, Hong M3, Van Vrancken M4, Lyou YJ2, Kim ST5, Park SH5, Kang WK5, Park YS5, Jung SH6, Woo M6, Lee J7, Kim KM8,9.
    View PubMed
  • Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • JOURNAL OF CLINICAL ONCOLOGY, APR 20 2016, 34(12):1422, DOI: 10.1200/JCO.2015.65.6975 Chemoradiotherapy in Gastric Cancer: A Door Ajar Reply Park SH1, Kang WK
    View PubMed
  • Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7. Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery Kim TG11, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
    View PubMed
  • Gut. 2015 Nov;64(11):1721-31. doi: 10.1136/gutjnl-2014-308252. Epub 2014 Nov 10. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas Lin SJ11, Gagnon-Bartsch JA2, Tan IB3, Earle S4, Ruff L4, Pettinger K4, Ylstra B5, van Grieken N5, Rha SY6, Chung HC6, Lee JS7, Cheong JH8, Noh SH8, Aoyama T9, Miyagi Y10, Tsuburaya A11, Yoshikawa T9, Ajani JA12, Boussioutas A13, Yeoh KG14, Yong WP15, So J16, Lee J17, Kang WK17, Kim S18, Kameda Y19, Arai T20, Zur Hausen A21, Speed TP22, Grabsch HI23, Tan P24.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Ann Oncol. 2015 Oct;26(10):2097-101. doi: 10.1093/annonc/mdv316. Epub 2015 Jul 27. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS) Ryu MH11, Baba E2, Lee KH3, Park YI4, Boku N5, Hyodo I6, Nam BH7, Esaki T8, Yoo C1, Ryoo BY1, Song EK9, Cho SH10, Kang WK11, Yang SH12, Zang DY13, Shin DB14, Park SR1, Shinozaki K15, Takano T16, Kang YK17; SOS study investigators.
    View PubMed
  • Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):316-25. doi: 10.1016/j.ijrobp.2015.05.023. Epub 2015 May 21. Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor Lim T11, Lee I2, Kim J3, Kang WK4.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24320-32. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
    View PubMed
  • Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Clin Transl Oncol. 2015 Jun;17(6):462-8. doi: 10.1007/s12094-014-1258-7. Epub 2014 Dec 2. The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer Kim ST11, Do IG, Lee J, Sohn I, Kim KM, Kang WK.
    View PubMed
  • Nat Med. 2015 May;21(5):449-56. doi: 10.1038/nm.3850. Epub 2015 Apr 20. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes Cristescu R11, Lee J2, Nebozhyn M1, Kim KM3, Ting JC4, Wong SS4, Liu J4, Yue YG4, Wang J4, Yu K4, Ye XS4, Do IG3, Liu S5, Gong L5, Fu J6, Jin JG6, Choi MG7, Sohn TS7, Lee JH7, Bae JM7, Kim ST2, Park SH2, Sohn I8, Jung SH8, Tan P9, Chen R1, Hardwick J1, Kang WK2, Ayers M1, Hongyue D1, Reinhard C4, Loboda A1, Kim S7, Aggarwal A4.
    View PubMed
  • Int J Cancer. 2015 Apr 1;136(7):1629-35. doi: 10.1002/ijc.29159. Epub 2014 Sep 4. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy Ha SY11, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM.
    View PubMed
  • Sci Rep. 2015 Mar 19;5:9289. doi: 10.1038/srep09289. The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer Lee JY11, Hong M2, Kim ST1, Park SH1, Kang WK1, Kim KM2, Lee J1.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21. Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Jung HA11, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Eur J Radiol. 2015 Jan;84(1):33-40. doi: 10.1016/j.ejrad.2014.10.020. Epub 2014 Nov 8. Gastrointestinal stromal tumours: Correlation of modified NIH risk stratification with diffusion-weighted MR imaging as an imaging biomarker Kang TW11, Kim SH2, Jang KM1, Choi D1, Ha SY3, Kim KM3, Kang WK4, Kim MJ5.
    View PubMed
  • Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • PLoS One. 2014 Nov 5;9(11):e111693. doi: 10.1371/journal.pone.0111693. eCollection 2014. High-Throughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer Kim S11, Lee J2, Hong ME3, Do IG3, Kang SY1, Ha SY1, Kim ST2, Park SH2, Kang WK2, Choi MG4, Lee JH4, Sohn TS4, Bae JM4, Kim S4, Kim DH5, Kim KM3.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • Anticancer Res. 2014 Nov;34(11):6585-91. Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study Lee SJ11, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim do H3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.
    View PubMed
  • Clin Genet. 2014 Jul;86(1):37-43. doi: 10.1111/cge.12408. Epub 2014 May 10. Innovative personalized medicine in gastric cancer: time to move forward Lee J11, Kim KM, Kang WK, Ou SH.
    View PubMed
  • Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90 alpha in human colorectal cancer
    View PubMed
  • Invest New Drugs.?2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Lee J11,?Hong YS,?Hong JY,?Han SW,?Kim TW,?Kang HJ,?Kim TY,?Kim KP,?Kim SH,?Do IG,?Kim KM,?Sohn I,?Park SH,?Park JO,?Lim HY,?Cho YB,?Lee WY,?Yun SH,Kim HC,?Park YS,?Kang WK.
    View PubMed
  • Ann Surg Oncol. 2014 Apr;21(4):1099-106. doi: 10.1245/s10434-013-3339-1. Epub 2013 Dec 4. CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer Ha SY11, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS.
    View PubMed
  • PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014. Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery Lee J11, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim do H6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.
    View PubMed
  • Int J Colorectal Dis. 2014 Feb;29(2):193-200. doi: 10.1007/s00384-013-1797-3. Epub 2013 Dec 10. Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients Kim TG11, Park W, Choi DH, Park HC, Kim SH, Cho YB, Yun SH, Kim HC, Lee WY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Chun HK.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Hong JY11, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.
    View PubMed
  • Invest New Drugs. 2013 Dec;31(6):1580-6. doi: 10.1007/s10637-013-0022-0. Epub 2013 Sep 7. Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients Lee SJ11, Lee J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kim KM, Do IG, Jung SH, Yim DS, Kang WK.
    View PubMed
  • J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26. Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia Qin S11, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y.
    View PubMed
  • Cancer Chemother Pharmacol. 2013 Apr;71(4):843-51. doi: 10.1007/s00280-013-2075-3. Epub 2013 Jan 13. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer Lee KH11, Chang HJ, Han SW, Oh DY, Im SA, Bang YJ, Kim SY, Lee KW, Kim JH, Hong YS, Kim TW, Park YS, Kang WK, Shin SJ, Ahn JB, Kang GH, Jeong SY, Park KJ, Park JG, Kim TY.
    View PubMed
  • Cancer Res. 2013 Feb 1;73(3):1056-62. doi: 10.1158/0008-5472.CAN-12-2498. Epub 2012 Dec 26. Unconventional Role of the Inwardly Rectifying Potassium Channel Kir2.2 as a Constitutive Activator of RelA in Cancer Lee I11, Lee SJ, Kang TM, Kang WK, Park C.
    View PubMed
  • Cancer Chemother Pharmacol. 2013 Jan;71(1):43-51. doi: 10.1007/s00280-012-1970-3. Epub 2012 Oct 7. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation Kang YK11, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    View PubMed
  • PLoS One. 2013;8(1):e54644. doi: 10.1371/journal.pone.0054644. Epub 2013 Jan 25. A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers Lee J11, Kim S, Kim P, Liu X, Lee T, Kim KM, Do IG, Park JO, Park SH, Jang J, Hoe N, Harvie G, Kuller A, Jain A, Meyer G, Leesman G, Park YS, Choi MG, Sohn TS, Bae JM, Lim HY, Singh S, Kang WK.
    View PubMed
  • BMC Cancer. 2012 Dec 13;12:596. doi: 10.1186/1471-2407-12-596. Statins and the risk of gastric cancer in diabetes patients Lee J11, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK.
    View PubMed
  • Mol Cancer Ther. 2012 Nov;11(11):2342-51. doi: 10.1158/1535-7163.MCT-12-0488. Epub 2012 Sep 10. Inhibition of Monocarboxylate Transporter 2 Induces Senescence-Associated Mitochondrial Dysfunction and Suppresses Progression of Colorectal Malignancies In Vivo Lee I11, Lee SJ, Kang WK, Park C.
    View PubMed
  • Gastric Cancer. 2012 Jul;15(3):292-8. doi: 10.1007/s10120-011-0104-7. Epub 2011 Oct 29. Lung metastases in metastatic gastric cancer: pattern of lung metastases and clinical outcome Kong JH11, Lee J, Yi CA, Park SH, Park JO, Park YS, Lim HY, Park KW, Kang WK.
    View PubMed
  • Cancer Chemother Pharmacol. 2012 May;69(5):1333-8. doi: 10.1007/s00280-012-1836-8. Epub 2012 Feb 5. Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer Lee DJ11, Sohn TS, Lim do H, Ahn HK, Park SH, Lee J, Park JO, Park YS, Lim HY, Choi DI, Kim KM, Choi MG, Noh JH, Bae JM, Kim S, Min BH, Kang WK.
    View PubMed
  • J Clin Oncol. 2012 Jan 20;30(3):268-73. doi: 10.1200/JCO.2011.39.1953. Epub 2011 Dec 19. Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial Lee J11, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK.
    View PubMed
  • Invest New Drugs. 2011 Dec;29(6):1449-58. doi: 10.1007/s10637-010-9438-y. Epub 2010 May 12. Phase II study of sunitinib as second-line treatment for advanced gastric cancer Bang YJ11, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A.
    View PubMed
  • Cancer Chemother Pharmacol. 2011 Jul;68(1):177-84. doi: 10.1007/s00280-010-1452-4. Epub 2010 Sep 28. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer Kim JA11, Lee J, Han B, Park SH, Park JO, Park YS, Lim HY, Kang WK.
    View PubMed
  • J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11. Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations Lee J11, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    View PubMed
  • Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration Ahn BJ11, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.
    View PubMed
  • Mol Cancer Ther. 2010 Nov;9(11):2951-9. doi: 10.1158/1535-7163.MCT-10-0511. Epub 2010 Sep 14. Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species-Mediated Cellular Senescence Lee I11, Park C, Kang WK.
    View PubMed
  • Cancer Res. 2010 Jun 1;70(11):4357-65. doi: 10.1158/0008-5472.CAN-09-3791. Epub 2010 May 11. A Novel Senescence-Evasion Mechanism Involving Grap2 and Cyclin D Interacting Protein Inactivation by Ras Associated with Diabetes in Cancer Cells under Doxorubicin Treatment Lee I11, Yeom SY, Lee SJ, Kang WK, Park C.
    View PubMed
  • J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16. Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Choi ER11, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.
    View PubMed
  • World J Gastroenterol. 2009 Oct 28;15(40):5086-90. Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases Oh SY11, Lee SJ, Lee J, Lee S, Kim SH, Kwon HC, Lee GW, Kang JH, Hwang IG, Jang JS, Lim HY, Park YS, Kang WK, Kim HJ.
    View PubMed
  • Cancer Chemother Pharmacol. 2009 Sep;64(4):657-63. doi: 10.1007/s00280-008-0913-5. Epub 2009 Jan 24. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study Lee J11, Jung KH, Park YS, Ahn JB, Shin SJ, Im SA, Oh do Y, Shin DB, Kim TW, Lee N, Byun JH, Hong YS, Park JO, Park SH, Lim HY, Kang WK.
    View PubMed
  • APMIS. 2009 Aug;117(8):598-606. doi: 10.1111/j.1600-0463.2009.02512.x. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma Lee J11, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim do H, Kim KM, Park CK.
    View PubMed
  • Cancer Chemother Pharmacol. 2009 May;63(6):1083-90. doi: 10.1007/s00280-008-0818-3. Epub 2008 Sep 24. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer Lee JJ11, Kim SY, Chung HC, Lee KH, Song HS, Kang WK, Hong YS, Choi IS, Lee YY, Woo IS, Choi JH.
    View PubMed
  • Ann Oncol. 2009 Apr;20(4):666-73. doi: 10.1093/annonc/mdn717. Epub 2009 Jan 19. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Kang YK11, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI.
    View PubMed
  • Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor Ryu MH11, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    View PubMed
  • Oncologist. 2009 May;14(5):540-7. doi: 10.1634/theoncologist.2008-0145. Epub 2009 May 2. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Kim TW11, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH, Kang WK, Shin DB, Bang YJ, Lee JS, Kang YK.
    View PubMed
  • A randomised multicentre phase II trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
  • Cancer Chemother Pharmacol. 2008 Jul;62(2):263-70. Epub 2007 Oct 25. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study Kim YH11, Chung HC, Kang WK, Park SR, Kim CS, Kim TY, Shin SW, Park BJ, Cha SJ, Bang YJ.
    View PubMed
  • Clin Cancer Res. 2008 Jan 1;14(1):82-8. doi: 10.1158/1078-0432.CCR-07-0612. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy Lee J11, Park CK, Park JO, Lim T, Park YS, Lim HY, Lee I, Sohn TS, Noh JH, Heo JS, Kim S, Lim do H, Kim KM, Kang WK.
    View PubMed
  • Yonsei Med J. 2007 Oct 31;48(5):827-32. Anal canal carcinoma: Experience from a single Korean institution Lee WS11, Chun HK, Lee WY, Yun SH, Yun H, Cho YB, Kang WK, Park YS, Huh SJ, Ahn YC, Park W.
    View PubMed
  • FEBS Lett. 2007 Aug 7;581(20):3800-4. Epub 2007 Jul 16. Inhibitory role of RhoA on senescence-like growth arrest by a mechanism involving modulation of phosphatase activity Park C11, Lee I, Jang JH, Kang WK.
    View PubMed
  • Jpn J Clin Oncol. 2007 Jul;37(7):501-8. Epub 2007 Aug 2. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea-Japan collaborative study group trial Kim YH11, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, Kang YK, Sakamoto J, Abe C, Sakata Y.
    View PubMed
  • Ann Oncol. 2007 May;18(5):886-91. Epub 2007 Feb 13. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma Lee J11, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK.
    View PubMed
  • Oncology. 2007;73(3-4):192-7. doi: 10.1159/000127386. Epub 2008 Apr 16. Clinical outcome of gastric cancer patients with bone marrow metastases Kim HS11, Yi SY, Jun HJ, Lee J, Park JO, Park YS, Jang J, Kim HJ, Ko Y, Lim HY, Kang WK.
    View PubMed
  • Ann Oncol. 2007 Jan;18(1):88-92. Epub 2006 Sep 13. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma Lee J11, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS.
    View PubMed
  • Mol Cancer Ther. 2006 Dec;5(12):3191-6. Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis Park C11, Lee I, Kang WK.
    View PubMed
  • Int J Mol Med. 2006 May;17(5):715-20. E2F-1 is a critical modulator of cellular senescence in human cancer Park C11, Lee I, Kang WK.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • Biochem Biophys Res Commun. 2006 Jan 20;339(3):748-54. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Lee J11, Lee I, Park C, Kang WK.
    View PubMed
  • Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85. Epub 2005 Aug 15. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach Kim S11, Lim DH, Lee J, Kang WK, MacDonald JS, Park CH, Park SH, Lee SH, Kim K, Park JO, Kim WS, Jung CW, Park YS, Im YH, Sohn TS, Noh JH, Heo JS, Kim YI, Park CK, Park K.
    View PubMed
  • Hepatocellular carcinoma with metastasis to the breast
  • Int J Mol Med. 2005 Oct;16(4):517-23. Neolignans from Saururus chinensis inhibit PC-3 prostate cancer cell growth via apoptosis and senescence-like mechanisms Song SY11, Lee I, Park C, Lee H, Hahm JC, Kang WK.
    View PubMed
  • Acta Oncol. 2005;44(3):230-5. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial Kim TW11, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR, Kim HK; Korean Cancer Study Group.
    View PubMed
  • Br J Cancer. 2005 May 23;92(10):1850-4. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer Kim ST11, Kang WK, Kang JH, Park KW, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Park K.
    View PubMed
  • Oncol Rep. 2005 Feb;13(2):299-304. Differential effects of RhoA signaling on anticancer agent-induced cell death Kang WK11, Lee I, Ko U, Park C.
    View PubMed
  • Am J Clin Oncol. 2004 Oct;27(5):477-80. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen Park SH11, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K.
    View PubMed
  • Br J Cancer. 2004 Jul 5;91(1):18-22. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer Lee SH11, Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park K.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed
  • Ann Oncol. 2003 Sep;14(9):1373-7. Postoperative chemoradiotherapy for gastric cancer Park SH11, Kim DY, Heo JS, Lim DH, Park CK, Lee KW, Choi SH, Sohn TS, Kim S, Noh JH, Kim YI, Park JO, Kim K, Kim WS, Jung CW, Im YH, Lee MH, Park K, Park CH, Kang WK.
    View PubMed
  • Br J Haematol. 2002 Nov;119(2):400-7. Monensin-mediated growth inhibition in human lymphoma cells through cell cycle arrest and apoptosis Park WH11, Seol JG, Kim ES, Kang WK, Im YH, Jung CW, Kim BK, Lee YY.
    View PubMed
  • Am J Clin Oncol. 2002 Aug;25(4):354-7. Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer Kim K11, Nam E, Lee NS, Lee HR, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK.
    View PubMed
  • Carcinogenesis. 2001 Oct;22(10):1727-31. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death Park C11, Lee I, Kang WK.
    View PubMed
  • Hum Gene Ther. 2001 Apr 10;12(6):671-84. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study Kang WK11, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH, Park K, Kim K, Jeong HS, Kim JA, Nam SJ, Yang JH, Son YI, Baek CH, Han J, Ree HJ, Lee ES, Kim SH, Kim DW, Ahn YC, Huh SJ, Choe YH, Lee JH, Park MH, Kong GS, Park EY, Kang YK, Bang YJ, Paik NS, Lee SN, Kim SH, Kim S, Robbins PD, Tahara H, Lotze MT, Park CH.
    View PubMed
  • Invest New Drugs. 2001;19(1):81-3. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma Kim WS11, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK.
    View PubMed